Is Wegovy Safe for Teenagers? The UK Licensing Reality

The misconception: that teen data means teen prescriptions are fine

A common assumption is that because semaglutide has been studied in adolescents (and some results published) it must be available to prescribe in the UK for that group. It is not. Clinical trials and regulatory approval are two separate things. A phase 3 trial (STEP TEENS, published in the New England Journal of Medicine) did examine 2.4 mg semaglutide weekly in adolescents aged 12–17 with obesity, and reported meaningful average weight reductions over 68 weeks. But a published trial does not create a UK marketing authorisation. The MHRA licenses medicines based on its own safety and efficacy review, and as of July 2026, Wegovy's UK authorisation covers adults only. The US Food and Drug Administration took a different regulatory decision; that is a different jurisdiction with no bearing on what can legally be prescribed here. Any online service offering Wegovy to a teenager in the UK is operating outside the authorised conditions for the medicine, that matters, and it should be a clear warning sign to families.

This is a question our prescribers hear most weeks, usually from parents who have read about the STEP TEENS trial or seen coverage of US approvals and are wondering why the UK hasn't moved at the same pace. The honest answer is that the MHRA sets its own bar, based on its own review, and the UK bar has not yet been met for under-18s.

What we do know about semaglutide's safety profile, and what remains uncertain in young people

In adults, the safety profile of semaglutide is relatively well characterised. The most common side effects are gastrointestinal: nausea, vomiting, constipation, diarrhoea and indigestion, generally peaking around dose increases and settling with time. The MHRA issued a Drug Safety Update in January 2026 specifically flagging acute pancreatitis as an infrequent but serious risk, with guidance to seek urgent help for severe stomach pain that spreads to the back. You can read about the broader adult side-effect picture on our Wegovy side effects page.

In adolescents, the picture is less established. The STEP TEENS trial reported a broadly similar tolerability profile to adults, but trial populations are not the same as real-world use at scale. Longer-term data in developing bodies (including effects on bone density, growth, nutritional status and reproductive development) are limited. Regulatory caution in this setting is appropriate. Parents should be sceptical of any service, UK or overseas, that minimises these gaps. A teenager's weight management should be directed by clinicians who have those gaps in their sightline, not around them. For those researching the general safety evidence base, parents often find it useful to start by understanding whether Wegovy is considered safe, before exploring the more specific long-term considerations documented on our long-term safety considerations for adults page.

The right path for a teenager with weight-related health concerns

If a young person's weight is affecting their health, the starting point in the UK is their GP. GPs can refer adolescents to NHS specialist paediatric weight management services, where clinicians trained in this age group will assess options, which may include structured lifestyle programmes, dietary support, psychological input, and, in specific clinical circumstances, medicines. Those medicines, where appropriate, are assessed and prescribed by paediatric specialists under clinical supervision, not by general online prescribing services.

For parents who are worried about waiting times or availability, the NHS England medicines-for-obesity overview at NHS England's medicines for obesity page sets out current pathways clearly. It does not make pleasant reading if waiting lists are long, but a specialist paediatric review is genuinely the clinically appropriate route. Online private prescribing services (including nume) prescribe only to adults. That is not a gap in our service; it reflects what is licensed, legal and safe.

What adults aged 18 and over should know about private Wegovy prescribing

Once someone turns 18, the adult licensing framework applies. Adults with a BMI of 30 or above, or 27 or above with a weight-related health condition, may be eligible for Wegovy as a private prescription following clinical assessment. Whether semaglutide is safe to take in any individual's specific circumstances depends on their medical history, current medicines and other factors, assessed by a prescriber, not a calculator. Adults who want to understand whether Wegovy is safe specifically for weight loss will find a detailed look at the evidence on that question in our dedicated guide, and a fuller guide to private treatment access at where to get Wegovy in the UK.

At nume, every consultation is read by a GPhC-registered prescriber, who makes a clinical judgement based on the full picture before any prescription is issued. If you are an adult looking for a clinically supervised, properly assessed route to weight management treatment, speaking to our prescribers is the place to start.